ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway

Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related deaths worldwide, accounting for nearly 800,000 fatalities annually. ITGAX (Integrin alpha X) is closely associated with immune cells, such as macrophages and dendritic cells. Its involvement in gastric can...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiali Hu, Jing Cao, Shanshan Huang, Yang Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1536478/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841555189374386176
author Jiali Hu
Jing Cao
Shanshan Huang
Yang Chen
Yang Chen
author_facet Jiali Hu
Jing Cao
Shanshan Huang
Yang Chen
Yang Chen
author_sort Jiali Hu
collection DOAJ
description Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related deaths worldwide, accounting for nearly 800,000 fatalities annually. ITGAX (Integrin alpha X) is closely associated with immune cells, such as macrophages and dendritic cells. Its involvement in gastric cancer was identified through an analysis of The Gene Expression Omnibus (GEO) database, which highlighted ITGAX as one of four key gastric cancer-related genes. Our study demonstrates that ITGAX expression is significantly elevated in tumor tissues compared to normal tissues and is positively correlated with clinical prognosis in gastric cancer patients from the GEO database. Moreover, ITGAX enhanced cell proliferation, invasion, and tumorigenic capacity in mouse models. Furthermore, we explored the underlying role of ITGAX using Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction networks (PPI) analysis. Our findings reveal that ITGAX promotes gastric cancer progression by driving epithelial-mesenchymal transition pathway (EMT), suggesting its potential as a biomarker for early diagnosis and prognosis in gastric cancer.
format Article
id doaj-art-bddf2dcbd74f4d81adc5c2cceff9e447
institution Kabale University
issn 1663-9812
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-bddf2dcbd74f4d81adc5c2cceff9e4472025-01-08T06:11:43ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15364781536478ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathwayJiali Hu0Jing Cao1Shanshan Huang2Yang Chen3Yang Chen4Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaSchool of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaGanjiang Chinese Medicine Innovation Center, Nanchang, ChinaKey Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, ChinaGastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related deaths worldwide, accounting for nearly 800,000 fatalities annually. ITGAX (Integrin alpha X) is closely associated with immune cells, such as macrophages and dendritic cells. Its involvement in gastric cancer was identified through an analysis of The Gene Expression Omnibus (GEO) database, which highlighted ITGAX as one of four key gastric cancer-related genes. Our study demonstrates that ITGAX expression is significantly elevated in tumor tissues compared to normal tissues and is positively correlated with clinical prognosis in gastric cancer patients from the GEO database. Moreover, ITGAX enhanced cell proliferation, invasion, and tumorigenic capacity in mouse models. Furthermore, we explored the underlying role of ITGAX using Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction networks (PPI) analysis. Our findings reveal that ITGAX promotes gastric cancer progression by driving epithelial-mesenchymal transition pathway (EMT), suggesting its potential as a biomarker for early diagnosis and prognosis in gastric cancer.https://www.frontiersin.org/articles/10.3389/fphar.2024.1536478/fullITGAXgastric cancerEMTcell migrationtumorigenesis
spellingShingle Jiali Hu
Jing Cao
Shanshan Huang
Yang Chen
Yang Chen
ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
Frontiers in Pharmacology
ITGAX
gastric cancer
EMT
cell migration
tumorigenesis
title ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
title_full ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
title_fullStr ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
title_full_unstemmed ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
title_short ITGAX promotes gastric cancer progression via epithelial-mesenchymal transition pathway
title_sort itgax promotes gastric cancer progression via epithelial mesenchymal transition pathway
topic ITGAX
gastric cancer
EMT
cell migration
tumorigenesis
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1536478/full
work_keys_str_mv AT jialihu itgaxpromotesgastriccancerprogressionviaepithelialmesenchymaltransitionpathway
AT jingcao itgaxpromotesgastriccancerprogressionviaepithelialmesenchymaltransitionpathway
AT shanshanhuang itgaxpromotesgastriccancerprogressionviaepithelialmesenchymaltransitionpathway
AT yangchen itgaxpromotesgastriccancerprogressionviaepithelialmesenchymaltransitionpathway
AT yangchen itgaxpromotesgastriccancerprogressionviaepithelialmesenchymaltransitionpathway